This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Vitamin E

Extensively Studied

Fat-soluble lipid-peroxidation chain breaker | 8-isoform tocopherol/tocotrienol family

Aliases (17)

alpha-tocopherol · α-tocopherol · mixed tocopherols · mixed tocotrienols · d-alpha-tocopherol · RRR-α-tocopherol · dl-alpha-tocopherol · all-rac-α-tocopherol · tocopheryl acetate · tocopheryl succinate · γ-tocopherol · γ-tocotrienol · δ-tocotrienol · AstaReal-not-applicable · vitamin-E · tocochromanols · VITAMIN E

TYPICAL DOSE

15 mg/day RDA

Daily

ROUTE

Oral (food preferred)

Food-source preferred; supplement only if deficient or NASH

CYCLE

None

Continuous at RDA; periodic if high-dose

STORAGE

Cool, dry, dark place

Cool, dry, dark — light degrades

Overview

What is Vitamin E?

Vitamin E is a fat-soluble vitamin family of 8 isoforms — α/β/γ/δ tocopherol and α/β/γ/δ tocotrienol — sharing a chromanol ring + isoprenoid tail. α-tocopherol is the form preferentially retained by hepatic α-TTP and the basis for the FDA RDA (15 mg/day). Functions primarily as a lipid-peroxidation chain breaker at cell membranes. Tolerable UL 1000 mg/day. Severe deficiency (AVED, abetalipoproteinemia, severe fat malabsorption) causes ataxia, neuropathy, and retinopathy.

Key Benefits

Genuine clinical value in deficiency correction and biopsy-proven non-diabetic NASH (PIVENS 800 IU/day). Foundational membrane antioxidant in the E → C → GSH redox cycle. Tocotrienols show distinct mechanisms (HMG-CoA reductase, NF-κB) with promising but underpowered RCTs. Food-source supplementation (sunflower seeds, almonds, spinach, olive oil) is preferred over pills for non-deficient adults — large RCTs have failed to show CV or cancer prevention benefit, and high-dose isolated α-tocopherol (≥400 IU/day) showed an all-cause mortality signal in Miller 2005.

Mechanism of Action

α-tocopherol donates a phenolic hydrogen to lipid peroxyl radicals (LOO·) at the membrane interface, breaking the chain-propagation step of polyunsaturated fatty acid oxidation. The resulting α-tocopheroxyl radical is recycled by ascorbate (vitamin C), then by glutathione — the foundational redox triad. γ-tocopherol uniquely traps reactive nitrogen species (peroxynitrite) and is depleted 30-50% by high-dose synthetic α-tocopherol supplementation. Tocotrienols additionally suppress HMG-CoA reductase, NF-κB, and modulate the ceramide pathway via mechanisms absent in tocopherols.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Research Indications

Most Effective

NF-κB inhibition

γ-tocotrienol blocks NF-κB activation in inflammatory and cancer cell models. Mechanism: prevents IκBα phosphorylation and IKK activation…

Effective

Ceramide pathway modulation

δ-tocotrienol increases ceramide accumulation in cancer cells via SPT (serine palmitoyltransferase) upregulation, contributing to apoptos…

Investigational

Estrogen receptor β agonism (γ-tocotrienol)

distinct from α-tocopherol; relevant to bone health and proliferative tissue context.

Peptide Interactions

Vitamin C (ascorbate)

Synergistic

recycles α-tocopheroxyl radical at the aqueous-lipid membrane interface; the foundational pairing. Consensus dosing: vitamin C 200-500 mg/day from food + sup…

Glutathione (GSH) / NAC

Synergistic

GSH regenerates dehydroascorbate to ascorbate, completing the redox triad. NAC supports GSH synthesis. The full E → C → GSH network is the integrated membran…

Selenium

Synergistic

cofactor for GPx4, which clears lipid hydroperoxides downstream of vitamin E's chain-breaking step. Adequate selenium status (~55-100 mcg/day, food-source: B…

Astaxanthin

Synergistic

both lipid-soluble membrane antioxidants; complementary positioning (astaxanthin spans the bilayer, α-tocopherol localizes near the aqueous interface). Often…

Fish oil (omega-3 / DHA)

Synergistic

PUFA-rich fish oil is highly susceptible to lipid peroxidation; vitamin E protects omega-3s from oxidation in the membrane and during storage. Most fish oil …

Coenzyme Q10 / ubiquinol

Synergistic

CoQ10 is a separate mitochondrial-membrane antioxidant; mechanism-aligned, no direct interaction. Acceptable co-administration.

Anticoagulants (warfarin, rivaroxaban, apixaban, dabigatran)

Avoid

high-dose vitamin E antagonizes vitamin K-dependent clotting factors and inhibits platelet aggregation. Monitor INR closely or avoid.

Antiplatelets (aspirin, clopidogrel, prasugrel)

Avoid

additive bleeding risk at high vitamin E doses.

High-dose synthetic α-tocopherol (>400 IU/day)

Avoid

in non-deficient adults — Miller 2005 mortality signal.

High-dose β-carotene (>15-20 mg/day) in current/former smokers

Avoid

CARET/ATBC concerns about carotenoid + smoking interaction; some carotenoid-vitamin E products bundle these; avoid.

Statins + niacin (HATS context)

Avoid

high-dose vitamin E may attenuate HDL response to statin/niacin combination; relevance at RDA unclear.

α-tocopherol + tocotrienol same-time dosing

Avoid

α-TTP displacement reduces tocotrienol uptake. Separate by 8-12 hours if both used.

Quality Indicators

✓

Natural d-alpha-tocopherol (RRR) labeling

Look for 'd-alpha-tocopherol' or 'RRR-α-tocopherol' on the label. Natural form is preferentially retained by α-TTP and ~1.5× more bioactive than synthetic dl-form.

✓

Mixed tocopherols formulation

Products labeled 'mixed tocopherols' include γ-, δ-, and β-tocopherol alongside α-tocopherol — preserves the γ-tocopherol that traps reactive nitrogen species and avoids α-driven displacement.

✓

Annatto-derived tocotrienols (DeltaGold)

If supplementing tocotrienols specifically, annatto-sourced (90% δ-tocotrienol, 10% γ-tocotrienol) avoids the α-tocopherol contamination of palm-derived products that can blunt tocotrienol activity.

Synthetic dl-alpha-tocopherol

Synthetic 'dl-alpha-tocopherol' or 'all-rac-α-tocopherol' contains 8 stereoisomers; only RRR is retained efficiently. Cheaper but lower bioactivity. Acceptable but suboptimal.

Tocopheryl acetate / succinate (esters)

Esterified forms are stable in capsules but require pancreatic esterase hydrolysis for absorption. Slightly slower onset but otherwise functional. Not a quality concern, just mechanistic context.

✗

High-dose isolated α-tocopherol (>400 IU/day)

Miller 2005 meta-analysis flagged dose-dependent all-cause mortality signal at ≥400 IU/day. ATBC and SELECT trials raised cancer concerns. Avoid chronic high-dose isolated α-tocopherol in non-deficient adults.

✗

No third-party COA for tocotrienol products

Tocotrienol products vary widely in actual content vs label. Demand a batch-specific COA for any tocotrienol supplement, as the WATCH-LIST mixed-tocotrienol category is unsettled.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (>10% at high doses):
- GI upset (bloating, loose stool, nausea) at 1000+ IU/day.
- Headache or fatigue at high chronic doses.
Less common (1-10% at high doses):
- Bleeding / bruising — high-dose vitamin E inhibits platelet aggregation (mild) and antagonizes vitamin K-dependent γ-carboxylation of clotting factors II, VII, IX, X. Increased bleeding risk especially in combination with anticoagulants/antiplatelets.
- Dizziness, blurred vision, weakness — high-dose only.
- Skin rash / hypersensitivity — rare.
Rare-serious (<1%):
- Hemorrhagic stroke — Physicians' Health Study II showed numerical (non-significant) increase. Theoretical concern from anticoagulant mechanism. Hard-block in users with prior hemorrhagic stroke history.
- Increased prostate cancer — SELECT trial signal (17% increased incidence at 400 IU/day). Mechanism unclear; possibly via γ-tocopherol displacement, possibly chance, but signal is real and replicated nowhere yet contradicted by no major positive trial.
- All-cause mortality at high doses — Miller 2005 dose-dependent signal at ≥400 IU/day. Even at 200 IU/day signal was equivocal.
- Heart failure — HOPE-TOO showed increased heart failure incidence at 400 IU/day (RR 1.13). Single trial signal.
Specific watch periods:
- Anticoagulants / antiplatelets: monitor INR closely; avoid high-dose vitamin E entirely if possible. RDA dose minimal risk.
- Pre-surgical: discontinue 1-2 weeks before any planned surgery if on >100 IU/day to reduce bleeding risk.
- Hereditary bleeding disorders (von Willebrand, hemophilia): avoid high-dose vitamin E.
- NASH protocol: baseline + periodic INR, lipid panel, ALT/AST, occasional vitamin E level.
Contraindications:
- Active bleeding diathesis.
- Vitamin K deficiency / warfarin without close monitoring.
- Prior hemorrhagic stroke (relative).
- Prostate cancer history (relative — given SELECT signal).

References

Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality. Ann Intern Med 2005;142:37-46. PMID 15537682

pubmed.ncbi.nlm.nih.gov · 2005

the foundational high-dose mortality signal meta-analysis. Pooled 19 trials, n=135,967; ≥400 IU/day all-rac-α-tocopherol associated with increased all-cause mortality.

Vitamin E

Overview

What is Vitamin E?

Key Benefits

Mechanism of Action

Pharmacokinetics

Research Indications

NF-κB inhibition

Ceramide pathway modulation

Estrogen receptor β agonism (γ-tocotrienol)

Peptide Interactions

Quality Indicators

Natural d-alpha-tocopherol (RRR) labeling

Mixed tocopherols formulation

Annatto-derived tocotrienols (DeltaGold)

Synthetic dl-alpha-tocopherol

Tocopheryl acetate / succinate (esters)

High-dose isolated α-tocopherol (>400 IU/day)

No third-party COA for tocotrienol products

What to Expect

Side Effects & Safety

References

Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality. Ann Intern Med 2005;142:37-46. PMID 15537682

Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685. PMID 20427778

The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035. PMID 8127329

Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-1556. PMID 21990298

Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (CARET). N Engl J Med 1996;334:1150-1155. PMID 8602180

Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P (HOPE Investigators). Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:154-160. PMID 10639539

GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. Lancet 1999;354:447-455. PMID 10465168

Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study. JAMA 2005;294:56-65. PMID 15998891

Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II. JAMA 2008;300:2123-2133. PMID 18997197

Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents (TONIC). JAMA 2011;305:1659-1668. PMID 21521847

Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-2023. PMID 12814712

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012;(3):CD007176. PMID 22419320

Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med 2007;43:4-15. PMID 17561088

Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med 2014;72:76-90. PMID 24814014

Aggarwal V, Kashyap D, Sak K, et al. Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements. Int J Mol Sci 2019;20:E1924. PMID 31137840

Magosso E, Ansari MA, Gopalan Y, et al. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver. Nutr J 2013;12:166. PMID 23656730

Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease (TEAM-AD). JAMA 2014;311:33-44.

Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. PNAS 2009;106:8665-8670.

Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington (DC): National Academies Press; 2000.

NIH Office of Dietary Supplements — Vitamin E Fact Sheet for Health Professionals

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-357.

Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease (HATS). N Engl J Med 2001;345:1583-1592.

Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer (HOPE-TOO). JAMA 2005;293:1338-1347.

See something off?

Related compounds